HRF

What HRF does

HRF, Inc. (formerly Hemophilia Relief Fund) is a privately held, FDA-regulated US Source Plasma Center founded in 1985 and headquartered in Raleigh, North Carolina. The company collects and distributes rare specialty human blood plasma from donors with diagnosed coagulation disorders, and has been majority owned and operated by individuals with coagulation disorders since inception. It operates from a single 3,500 ft² facility that includes a donor collection room, laboratory, freezer room, and climate-controlled units with continuous remote monitoring, supported by roughly 138 years of combined staff experience across hemophilia, laboratory procedures, phlebotomy, and plasmapheresis.

Its product portfolio consists of 19 specialty plasma SKUs covering deficiency variants for Factors V, VII, VIII (including Deficient, Pooled, and with Inhibitor), IX, X, XI, XII, and Fletcher Factor, plus Von Willebrand Disease Types 1, 2B, and 3, Lupus Anticoagulant, Activated Protein C Resistant, Coumarin, and Normal/Pooled variants. All products are non-injectable and intended for further manufacturing into in vitro diagnostic reagents, research and development of clotting concentrates, and genetic-discovery research related to hemophilia cures. The proprietary process is based on manual plasmapheresis using refrigerated centrifuges, combined with proprietary donor screening and processing procedures developed over decades.

HRF sells direct to international research institutions and diagnostic product manufacturers via a sales-led B2B model requiring hard-copy purchase orders, with quote-based pricing on a per-milliliter basis, NET 30 terms, and FedEx Priority Overnight (domestic) or FedEx International (international) shipping on dry ice. The company charges handling fees of $100 USD per box domestically and $150 USD internationally. Its customer base spans the United States, Spain, France, England, Germany, China, South Africa, and Latin America. HRF holds an FDA variance permitting collection from HCV antibody-positive donors, materially expanding its eligible donor pool. The firm is founder-owned, has no disclosed institutional investment, no acquisitions, no product launches beyond incremental SKU additions, and no publicly disclosed revenue or headcount figures.

Name

HRF

Legal name

HRF, Inc.

Website

https://hrfinc.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

51–100 employees

Short description

HRF, Inc. is a privately held, FDA-regulated US specialty plasma company that collects rare human blood plasma from donors with coagulation disorders and sells 19 factor-deficient and specialty plasma products to international research institutions and diagnostic manufacturers for in vitro diagnostic, clotting-concentrate R&D, and hemophilia cure research.

Ownership category

akta.pro rank

Product category

Specialty Plasma Products

NAICS

Blood and Organ Banks (621991)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK), Plasma-Derived & Blood Products Distributors (HLAIAJAJ), Plasma-Derived Therapy Cold Chain & Specialty Logistics (HLAIAHAL)

Keywords

• Specialty plasma products
• Human blood plasma
• Coagulation disorder plasma
• Diagnostic reagent materials
• Plasmapheresis collection

Headquarters

HQ city

Dickson

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Plasma Product Sales: Sale of specialty human blood plasma products to international market for manufacturing into in vitro diagnostic products, research and development of clotting concentrates, and genetic discovery research. Products include various factor deficient plasmas and specialty coagulation products.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

HRF, Inc. collects and distributes 19 specialty human blood plasma products sourced from donors with rare coagulation disorders. The plasma is intended for further manufacturing into in vitro diagnostic reagents, research and development of clotting concentrates, and genetic-discovery research for hemophilia and related disorders. All products are non-injectable and supplied to the international market for diagnostic and research applications.

Product overview

HRF, Inc. is a specialty plasma products company that collects and distributes rare human blood plasma from donors with coagulation disorders. The company operates as a single-product portfolio consisting of 19 distinct specialty plasma products, including Factor VIII variants (Deficient, Pooled, and with Inhibitor), various Factor deficiencies (V, VII, IX, X, XI, XII), Von Willebrand Disease types (1, 2B, 3), and specialized plasmas (Lupus Anticoagulant, Activated Protein C Resistant, Coumarin, Fletcher Factor). All products are intended for further manufacturing into in vitro diagnostic reagents for non-injectable use. The company serves the international research and diagnostic manufacturing community, with clients in the US, Spain, France, England, Germany, and Asian countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Factor VIII Deficient Plasma Specialty human blood plasma from donors with Factor VIII deficiency, intended for further manufacturing into in vitro diagnostic reagents and research into clotting therapies for hemophilia A.
• Factor VIII Pooled Plasma Pooled plasma from multiple donors with Factor VIII deficiency, intended for further manufacturing into in vitro diagnostic products.
• Factor VIII with Inhibitor Plasma Specialty plasma from donors who have developed inhibitors to Factor VIII, used for research and development of clotting concentrates.
• Factor V Deficient Plasma Plasma deficient in Factor V coagulation factor, intended for further manufacturing into in vitro diagnostic reagents.
• Factor VII Deficient Plasma Plasma deficient in Factor VII, intended for further manufacturing into in vitro diagnostic reagents.
• Factor IX Deficient Plasma Plasma deficient in Factor IX, intended for further manufacturing into in vitro diagnostic reagents.
• Factor IX Pooled Plasma Pooled plasma from multiple donors with Factor IX deficiency, intended for diagnostic product manufacturing.
• Factor X Deficient Plasma Plasma deficient in Factor X, intended for further manufacturing into in vitro diagnostic reagents.
• Factor XI Deficient Plasma Plasma deficient in Factor XI, intended for further manufacturing into in vitro diagnostic reagents.
• Factor XII Deficient Plasma Plasma deficient in Factor XII (Hageman factor), intended for further manufacturing into in vitro diagnostic reagents.
• Von Willebrand Plasma Type 1 Plasma from donors with Type 1 Von Willebrand disease, intended for further manufacturing into in vitro diagnostic reagents.
• Von Willebrand Plasma Type 2B Plasma from donors with Type 2B Von Willebrand disease, intended for further manufacturing into in vitro diagnostic reagents.
• Von Willebrand Plasma Type 3 Plasma from donors with Type 3 (severe) Von Willebrand disease, intended for further manufacturing into in vitro diagnostic reagents.
• Lupus Anticoagulant Plasma Plasma containing lupus anticoagulant antibodies, intended for research and diagnostic reagent manufacturing.
• Activated Protein C Resistant Plasma Plasma from donors showing resistance to activated Protein C, intended for diagnostic reagent manufacturing.
• Coumarin Plasma Plasma from donors on anticoagulant (coumarin) therapy, providing a wide range of INR values for testing purposes.
• Fletcher Factor (Prekallikrein) Deficient Plasma Plasma deficient in Fletcher Factor (Prekallikrein), intended for further manufacturing into in vitro diagnostic reagents.
• Normal Plasma Standard normal human plasma from donors without coagulation disorders, intended for quality control and diagnostic reagent manufacturing.
• Normal Pooled Plasma Pooled plasma from multiple normal donors, intended for further manufacturing into in vitro diagnostic reagents.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered minor.

• National Hemophilia FoundationminorOthersIndustry association providing resources and information on bleeding and coagulation disorders. Listed as a resource link on HRF website for patients and families.
• Hemophilia Federation of AmericaminorOthersIndustry association providing support and education for individuals with bleeding disorders. HRF participates in their annual symposium events.
• World Federation of HemophiliaminorOthersInternational organization dedicated to improving and sustaining care for people with hemophilia and related inherited bleeding disorders. HRF participates in their World Congress events.
• University of North Carolina Comprehensive Hemophilia CenterminorOthersRegional medical center specializing in hemophilia treatment. Listed as a resource link for patient referrals and information.
• Hemophilia of North CarolinaminorOthersState-level organization providing support for hemophilia patients in North Carolina. Listed as a resource link for local patient support.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hyphen BioMed (part of Sysmex): Specialty supplier of coagulation and thrombosis research reagents, including factor deficient plasmas and specialty controls. Directly comparable niche specialty product offering targeting hemostasis research and IVD manufacturers.
• Affinity Biologicals: Canadian specialty manufacturer of coagulation factor deficient plasmas and antibody products used in IVD reagent manufacturing and hemostasis research. Directly comparable to HRF in product mix, customer base (diagnostic manufacturers and research labs), and distribution model.
• Haematologic Technologies (HTI): US-based supplier of coagulation factor deficient plasmas, purified proteins, and specialty blood products for diagnostic and research use. Closely comparable to HRF in addressing IVD manufacturers and hemostasis research customers with rare factor-deficient plasma inputs.
• George King Bio-Medical: Specialty plasma and biological specimen supplier focused on rare and disease-state plasma products for diagnostic and research applications. Comparable to HRF in serving IVD manufacturers with specialty coagulation and disease-state plasma inputs.
• Precision BioLogic: Developer of coagulation diagnostic reagents and specialty plasmas used by clinical labs worldwide. Comparable to HRF in product line (specialty coagulation plasma) and end customers (diagnostic labs and IVD manufacturers), though with broader finished-kit offerings.
• DiaPharma Group: US distributor and supplier of hemostasis and coagulation diagnostic reagents and specialty plasma products. Comparable to HRF in serving clinical labs and diagnostic manufacturers with rare coagulation inputs, though primarily a distribution channel for others' products.

Broad incumbents

• Sekisui Diagnostics (formerly American Diagnostica / Bioveris): Broad diagnostic manufacturer with established coagulation and specialty hemostasis product lines. Overlaps with HRF's customer base and product category but operates at significantly larger scale across general IVD reagent categories.
• LGC Group (formerly SeraCare Life Sciences): Large specialty biological products provider including disease-state plasma and diagnostic reference materials. Broader portfolio than HRF but overlapping customer base in IVD manufacturers and reference labs requiring specialty biological inputs.
• Bio-Rad Laboratories: Large diversified diagnostics and life science manufacturer with quality control plasma products and hemostasis reagent lines. Overlaps with HRF in IVD input supply but at much greater scale and across broader product categories.
• Siemens Healthineers (Hemostasis/Coagulation): Global diagnostics leader with extensive hemostasis and coagulation testing product lines. While not a specialty plasma producer, competes indirectly by integrating plasma-based diagnostics into broader automated lab systems that displace specialty reagent demand.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/?lang=en
• LinkedInlinkedin.com/company/hrf-inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HRF